Vor Biopharma Inc (VOR)

Currency in USD
19.420
+0.100(+0.52%)
Closed·
19.200-0.220(-1.13%)
·
Advertisement
VOR is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
18.16019.490
52 wk Range
6.50026.000
Key Statistics
Prev. Close
19.42
Open
19.32
Day's Range
18.16-19.49
52 wk Range
6.5-26
Volume
739.31K
Average Volume (3m)
927.48K
1-Year Change
94.006%
Book Value / Share
-2.32
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
VOR Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
39.000
Upside
+100.82%
Members' Sentiments
Bearish
Bullish
ProTips
2 analysts have revised their earnings upwards for the upcoming period

Vor Biopharma Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Strong Buy
Moving Averages
Neutral

Analyst Ratings

9 Buy
1 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 39.000
(+100.82% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Stifel
Buy40.00+105.97%-Maintain02/11/2026
William Blair
Buy---New Coverage21/10/2026
Stifel
Buy40.00+105.97%-Maintain28/09/2026
H.C. Wainwright
Buy31.00+59.63%32.00Maintain15/04/2026
Stifel
Buy40.00+105.97%-Maintain08/04/2026

Vor Biopharma Inc SWOT Analysis


AML Breakthrough
Vor Biopharma's trem-cel + Mylotarg combo shows promise in improving relapse-free survival for AML patients, with key data expected in 2025
Financial Runway
$91.9M cash position and $56M PIPE extend operations into Q1 2026, supporting critical clinical milestones despite negative EPS forecasts
Market Potential
Analyst price targets range from $5 to $18, reflecting significant upside potential in the competitive oncology therapeutics landscape
Strategic Expansion
Explore Vor's plans for a pivotal two-year controlled trial and potential applications of its technology beyond AML, diversifying its pipeline
Read full SWOT analysis

Earnings

Latest Release
30/10/2026
EPS / Forecast
-1.45 / -0.82
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

Compare VOR to Peers and Sector

Metrics to compare
VOR
Peers
Sector
Relationship
P/E Ratio
0.9x−3.8x−0.2x
PEG Ratio
0.01−0.030.00
Price/Book
−8.7x1.8x2.6x
Price / LTM Sales
-130.2x2.8x
Upside (Analyst Target)
100.8%153.9%65.0%
Fair Value Upside
Unlock4.4%9.5%Unlock

Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren’s disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
14.58M23.74%283.24M
Other Institutional Investors
69.19M76.26%1.34B
Public Companies & Retail Investors
0.000.00%0.00
Total
83.78M100.00%1.63B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
FMR LLC11.00%6,758,967131,259
TCG Crossover Management, LLC9.23%5,673,078110,171

People Also Watch

11.37
JANX
-1.13%
15.660
ERAS
-0.76%
7.860
ORIC
-7.53%
43.21
SRRK
+0.12%
127.57
KYMR
+0.31%

FAQ

What Is the Vor Biopharma (NASDAQ: VOR) Share Price Today?

The Vor Biopharma stock price today is 19.420 USD.

What Stock Exchange Does Vor Biopharma (VOR) Trade On?

Vor Biopharma is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Vor Biopharma?

The stock symbol (also called a 'ticker') for Vor Biopharma is "VOR."

What Is the Current Vor Biopharma Market Capitalisation?

As of today, Vor Biopharma (NASDAQ: VOR) market cap is 1.190B USD.

What Is Vor Biopharma's (VOR) Earnings Per Share (TTM)?

The Vor Biopharma EPS is currently 30.51 (Trailing Twelve Months).

When Is the Next Vor Biopharma Earnings Date?

Vor Biopharma's next earnings report will be released on 25/03/2027.

Is VOR a Buy or Sell From a Technical Analyst Perspective?

Based on today's Vor Biopharma moving averages and other technical indicators, the daily buy/sell signal for VOR stock is Strong Sell.

How Many Times Has Vor Biopharma Stock Split?

Vor Biopharma has split 1 times. (See the VOR stock split history page for full effective split date and price information.)

How Many Employees Does Vor Biopharma Have?

Vor Biopharma has 76 employees, based on their latest Companies House report.

What is the current trading status of Vor Biopharma (NASDAQ: VOR)?

As of 16/11/2026, Vor Biopharma (VOR) is trading at a share price of 19.420 USD, with a previous close of 19.420 USD. The stock has fluctuated within a day range of 18.160 USD to 19.490 USD, while its 52-week range spans from 6.500 USD to 26.000 USD.

What Is Vor Biopharma (VOR) Price Target According to Analysts?

The average 12-month price target for Vor Biopharma is 39.000 USD, with a high estimate of 50 USD and a low estimate of 27 USD. 9 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +100.82% Upside potential.

What Is the VOR After Hours Price?

VOR's last after hours stock price is 19.200 USD, the stock has decreased by -0.220, or -1.130%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.